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The participation of children in research honours their right to
equal consideration by enabling their access to safe and
effective health care products.1 There has been an increasing
call for research initiatives to involve children.2 However,
children are considered vulnerable3 and most ethical guidelines
spell out protections for them. These generally include the
absence of alternative methods or research participants,
acceptable levels of research risk, consent by parents or legal
guardians and child assent.1
The South African AIDS Vaccine Initiative (SAAVI), a lead
programme of the Medical Research Council (MRC), is
currently focusing on healthy adult participants who can give
independent consent for HIV vaccine trial participation.
However, children in South Africa are at considerable risk of
HIV infection.  A recent study4 revealed that 7% of 2 - 9-year-
olds and 5% of 10 - 18-year-olds are infected with HIV.  HIV-
preventive vaccines may constitute one critical preventive
intervention for children. It will be necessary to enrol children
in HIV vaccine trials to generate data on the safety,
immunogenicity and efficacy of HIV vaccines for this
population. 
However, the participation of South African children in HIV
vaccine trials presents a number of ethical-legal challenges.
Challenges include the nature of research in which it is
considered permissible to enrol children, and post-enrolment
challenges such as management of child disclosure of high-risk
sexual behaviour or illegal activities. 
In this article we restrict ourselves to the challenges
presented by one set of influential ethical guidelines, the
Medical Research Council (MRC)’s Guidelines on Ethics for
Medical Research: General Principles (Book 1)5 to the enrolment of
healthy children in HIV-preventive vaccine research, and make
recommendations for revision of these guidelines.
MRC 2001 general principles: Book 1     
Those who formulate guidelines and regulations have long
struggled with the problem of how to promote the best
interests of children as a group through research while
protecting the rights and welfare of individual research
subjects.1
Book 15 governs MRC-funded research, and researchers. Its
provisions on research involving children appear to be more
restrictive than other South African guidelines6 and rest on a
number of conceptually confusing provisions. The latter relate
to the classification of research as ‘therapeutic’ or ‘non-
therapeutic’ and as ‘intervention’ or ‘observation’. 
According to Book 1, when research is classified as ‘non-
therapeutic’ and as ‘intervention’, children are precluded from
participation.   
‘Therapeutic’ versus ‘non-therapeutic’
research
This distinction has been defined as the difference between
research where the aim is essentially diagnostic or therapeutic
for a patient, and research where the aim is purely scientific.7
‘Therapeutic’ studies have been defined as those that seek
generalisable knowledge but intend to provide medically
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Children are at risk of HIV infection, stand to benefit from the
development of HIV preventive vaccines, and therefore
should be enrolled in trials of HIV vaccines in order to
generate relevant safety, immunogenicity and efficacy data. In
South Africa, the national vaccine initiative is considering the
future conduct of trials involving children; this requires an
analysis of the current ethical framework, including elements
that facilitate or constrain the conduct of such trials. In this
article, we examine the Medical Research Council (MRC)’s
Guidelines on Ethics for Medical Research: General Principles
(Book 1), and their provisions on research involving children.
We argue that this set of influential guidelines includes
provisions on research with children that are conceptually
problematic and may prohibit critical research with healthy
(but at-risk) child participants, including trials of HIV-
preventive vaccines. We recommend that Book 1 provisions
should be redrafted to reflect a balance between protecting
children from research-related risks and testing interventions
critical to their health.
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beneficial and acceptable therapy for the individual, and ‘non-
therapeutic’ studies have been defined as those that seek
generalisable knowledge but do not intend to provide therapy
to benefit the individual directly.1
This is a contested distinction on the grounds that most trials
will contain components or interventions that do not intend to
confer a direct health-related benefit to individual volunteers,
e.g. assignment to placebo, additional tests.8 A number of
leading international guidelines have abandoned this
distinction.9,10 However, MRC Book 1 structures its provisions
on children around this distinction.  
Book 1 appears to classify research as ‘therapeutic’ or ‘non-
therapeutic’ according to the aim of the research and the health
status of participants. Specifically, therapeutic research is
defined as aiming to benefit the individual participant or
patient by treating or curing his or her condition, or
investigating an intervention that might be of therapeutic
benefit to the patient. Book 1 states that in most cases, research
on patients will be therapeutic research. Non-therapeutic
research is defined as aiming to acquire knowledge and to
benefit people other than the research participant. Book 1 states
that ‘by definition’ healthy volunteers will not be participants
in therapeutic research but will participate in non-therapeutic
research.
It may be difficult to classify research according to these
definitions, particularly research involving the participation of
volunteers who may be healthy but, because of their risk or
susceptibility to a condition, stand to benefit from the
intervention under testing.  For example, phase III HIV vaccine
trials may test promising candidate vaccines that could be of
direct benefit to (at-risk) individual volunteers although
volunteers are healthy. These trials could, therefore, be seen to
meet part of the MRC defining elements for therapeutic and
non-therapeutic research. 
HIV vaccine trials, however, might be crudely categorised as
non-therapeutic, because Book 1 asserts that ‘by definition’
healthy volunteers will not be participants in therapeutic
research, or because they comprise early safety or
immunogenicity studies. 
‘Observation’ versus ‘intervention’
research
MRC Book 1 classifies research as ‘intervention’ or
‘observation’ research. Intervention research is defined as
research that interferes with a research participant’s mental or
physical integrity, and always involves risks of unpredictable
magnitude. Examples given include the removal of bodily
material, or the introduction of fluids into the body.
Observation research is not defined per se but is classified
further as non-invasive research involving no interference with
mental or physical integrity and no risk (e.g. unlinked
anonymous specimen gathering), and ‘invasive’ research that
invades mental or physical integrity but involves ‘negligible
risk’ foreseeable from routine medical practice (e.g. the
collection of urine, nail clippings, hair, one blood sample,
weight measurements). ‘Negligible risk’ is defined as equal to
the probability and magnitude of physical or psychological
harm that is normally encountered in the daily lives of people
in a stable society or in the routine performance of physical or
psychological examinations or tests — so-called everyday risk.
It is not simple to classify research according to these
definitions. To do so, procedures must be examined (namely,
do the procedures invade the integrity of the participant?).
Invasive procedures characterise both ‘types’ of research,
therefore it is risks that appear more important — both risk
level (are risks commensurate with those of routine medical or
psychological examinations or not?) and risk foreseeability (are
the risks foreseeable from routine medical practice?).  
However, using the research types, risk levels and examples,
it would appear that trials of HIV vaccines would be classified
as ‘intervention’ research, because such trials do interfere with
the bodily integrity of participants, will exceed ‘negligible’ risk
(also defined as risk so small it may be ignored) and involve
the introduction of fluids or agents into the body.  
Child participation in non-therapeutic
research — observation only
MRC Book 1 does not permit the participation of children in
non-therapeutic intervention research. It only permits the
participation of children in non-therapeutic observation
research of an invasive or non-invasive nature. 
‘Non-therapeutic research on minors is not permissible,
except where parental consent (and the assent of the minor) is
obtained for observation research of a non-invasive nature ...
and observation research of an invasive nature ...’5 pp. 12 - 13).
Parental consent and child assent are restricted to this kind of
study. Therefore, Book 1 provisions as currently drafted may
preclude parental consent to enrol healthy children in clinical
trials of HIV vaccines. 
Parental consent for non-therapeutic research is also
restricted to research with a risk threshold of ‘no or negligible
risk’. This appears more restrictive than other regulations and
guidelines. For example, the US Code of Federal Regulations11
allows that parents may give proxy consent to non-beneficial
research if the risks are reasonably commensurate with those of
a child’s non-research life; however, a minor increase over such
risk may be considered acceptable if the research holds out the
prospect of potential benefit to others in the same class.12 The
guidelines of the Council for International Organisations of
Medical Sciences (CIOMS)10 explicitly allow children to be
enrolled in research representing a minor increase over
everyday risk, even where the research interventions do not
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hold out the prospect of direct benefit for the subject, when
there is an overriding scientific or medical rationale, or where
the research is designed to be responsive to conditions to
which children are particularly susceptible.
Conclusions and recommendations
Current MRC 2001 provisions may have consequences that the
drafters did not foresee.8 In order to justify intervention
research on preventive agents with healthy children, under
current MRC provisions, investigators might have to argue that
such trials are in fact ‘therapeutic research’. This would be
difficult because of the assertion that healthy volunteers do not
participate in ‘therapeutic’ research.  Alternatively,
investigators might have to acknowledge that trials of
preventive agents involving healthy children are likely to be
classified as ‘non-therapeutic’ research, but might try to argue
that such research is not ‘intervention’ research, but rather
observational research of an invasive nature. Meeting the
outlined risk standard or the examples will prove a challenge. 
Instead, we recommend that the MRC consider a careful
revision of these provisions on research with children to reflect
a balance between the need to protect children from research-
related risks while permitting critical research for the health of
children.  Specific recommendations include the following.
1. The classification of entire protocols as ‘therapeutic’ or
‘non-therapeutic’ should be omitted and replaced with a focus
on beneficial versus non-beneficical interventions.13
2. Risk standards and risk-benefit ratios for interventions
with children should be carefully framed, e.g. the risks from
non-beneficial interventions should be commensurate with
routine examinations or tests, or slighter higher when there is
an overriding scientific or medical rationale.10 Risks from
beneficial interventions should be outweighed by the benefits.
3. Trials of HIV vaccines involving healthy child participants
should be permitted when certain safeguards prevail, e.g. (i) if
the research cannot be conducted equally well on adults; (ii) if
interventions meet risk standards and risk-benefit ratios
outlined above; (iii) legal requirements for consent and assent
are obtained; and (iv) due consideration is undertaken by
research ethics committees with appropriate child expertise.  
The HIV AIDS Vaccines Ethics Group is funded by the South
African AIDS Vaccine Initiative. Ann Strode and Melissa Stobie are
thanked for their helpful comments, and Nicola Barsdorf for
manuscript preparation.
References
1.   Kopelman L. Children as research subjects: A dilemma. J Med Philos 2000; 25: 745-764.
2.   National Institutes of Health. NIH policy and guidelines on the inclusion of children
as participants in research involving subjects. 1998. Available from
http://grants.nih.gov/grants/guide/notice-files/not98-024.html (last accessed 30
September  2004).
3.   Glantz LH. Research with children. Am J Law Med 1998; 24: 213-244. Available from
http://articles.findarticles.com/p/articles/mi_m6029/is_n2-3_24/ai_21115494 (last
accessed 11 October  2004).
4.   Human Sciences Research Council of South Africa. Study on HIV/AIDS in children.
2002. Available from http://www.hsrc.ac.za/media/2004/5/20040512_2.html (last
accessed 11 October 2004).
5.   Medical Research Council. Guidelines on ethics or medical research: General
Principles. 2001. Available from URL
http://www.sahealthinfo.org/ethics/ethicsbook1.pdf (last accessed 15 December
2004).
6.   Department of Health. Guidelines for good practice in the conduct of clinical trials in
South Africa 2000. Available from http://www.doh.gov.za/docs/policy/trials
/trials_contents.html (last accessed 17 December 2004).
7.   World Medical Association. Declaration of Helsinki. 1989. Available from
http://www.wma.net/e/policy/b3.htm (last accessed 10 January 2005).
8.   Levine R. The need to revise the Declaration of Helsinki. N Engl J Med 1999; 341: 531-
534.
9.   World Medical Association. Declaration of Helsinki. 2000. Available from
http://www.wma.net/e/policy/b3.htm (last accessed 10 December 2004).
10. Council for International Organisations of Medical Sciences (CIOMS).  International
ethical guidelines for biomedical research involving human subjects. 2002. Available
from http://www.cioms.ch/frame_guidelines_nov_2002.htm (last accessed 10
December 2004).
11. US Federal Government. Code of Federal Regulations. Available from
http://www.gpoaccess.gov/cfr/index.html (last accessed 10 December 2004).
12. Nelson R. Children as research subjects. In: Kahn JP,  ed.  Beyond Consent. New York:
Oxford University Press, 1998: 47-66.
13. Weijer C. The ethical analysis of risk. J Law Med Ethics 2000; 28: 344-361.
Accepted 8 March 2005.
271
April 2005, Vol. 95, No. 4  SAMJ
340257-269-271-SMJ0405  3/4/05  11:10  Page 271
